Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK-cell activity

Carter M. Suryadevara, Katherine A. Riccione, John H. Sampson

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma.

Original languageEnglish
Pages (from-to)5164-5166
Number of pages3
JournalClinical Cancer Research
Volume22
Issue number21
DOIs
StatePublished - 1 Nov 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Immunotherapy gone viral: Bortezomib and oHSV enhance antitumor NK-cell activity'. Together they form a unique fingerprint.

Cite this